Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device

International Journal of Pharmaceutics

Volumn 245, Issue 1-2, 2002, Pages 123-132

  Ball, Denise J ^a   Hirst, Peter H ^a   Newman, Stephen P ^a   Sonet, Bernard ^b   Streel, Bruno ^b   Vanderbist, Francis ^b  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b SMB Galephar Pharmaceuticals   (Belgium)

Author keywords

Asthma; Corticosteroids; Drug deposition; Dry powder inhalers; Pharmacokinetics

Indexed keywords

BUDESONIDE; TECHNETIUM 99M;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BREATHING; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVICE; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRY POWDER; FEMALE; GAMMA SCINTIGRAPHY; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LUNG FUNCTION; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AEROSOLS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; CROSS-OVER STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; ISOTOPE LABELING; MALE; METERED DOSE INHALERS; MIDDLE AGED; RADIOIMMUNODETECTION; RANDOMIZED CONTROLLED TRIALS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0036804025     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00338-1     Document Type: Article

References (32)

1. Bondesson E., Asking L., Borgström L., Nilsson L.-E., Trofast E., Wollmer P. In vitro and in vivo aspects of quantifying intrapulmonary deposition of a dry powder radioaerosol. Int. J. Pharm. 232:2002;149-156.
2. Borgström L., Bondesson E., Morén F., Trofast E., Newman S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7:1994;69-73.
3. Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Brugt J.V., Donnell D., Hannon S., Colice G.L. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. 104:1999;1215-1222.
4. Cass L.M.R., Brown J., Pickford M., Fayinka S., Newman S.P., Johansson C.J., Bye A. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. 36:(Suppl. 1):1999;21-31.
5. Clark A.R. Medical aerosol inhalers: past, present and future. Aerosol Sci. Technol. 22:1995;374-391.
6. Dolovich M.B. New propellant-free technologies under investigation. J. Aerosol Med. 12:(Suppl. 1):1999;S9-S17.
7. Farr S.J. The physicochemical basis of radiolabelling metered dose inhalers with 99mTc. J. Aerosol Med. 9:(Suppl. 1):1996;S27-S36.
8. Farr S.J., Warren S.J., Lloyd P., Okikawa J.K., Schuster J.A., Rowe A.M., Rubsamen R.M., Taylor G. Comparison of in vitro and in vivo efficiencies of a novel unit-dose aerosol generator and a pressurized metered dose inhaler. Int. J. Pharm. 198:2000;63-70.
9. Hill M., Vaughan L., Dolovich M. Dose targeting for dry powder inhalers. Dalby R.N., Byron P.R., Farr S.J., Respiratory Drug Delivery V. 1996;197-208 Interpharm Press, Buffalo Grove.
10. Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 12:1998;1346-1353.
11. Lipworth B.J. Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 42:1996;697-705.
12. Lucas P., Anderson K., Potter U.J., Staniforth J.N. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm. Res. 16:1999;1643-1647.
13. Meakin B.J., Cainey J.M., Woodcock P.M. Drug delivery characteristics of Bricanyl Turbuhaler dry powder inhalers. Int. J. Pharm. 119:1995;91-102.
14. Newman S.P., Morén F., Trofast E., Talaee N., Clarke S.W. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur. Respir. J. 2:1989;247-252.
15. Newman S.P. Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Therap. Drug Carrier Syst. 10:1993;65-109.
16. Newman S.P. New aerosol delivery systems. Barnes P.J., Grunstein M.M., Leff A.R., Woolcock A.J., Asthma. 1997;1805-1815 Lippincott-Raven, Philadelphia.
17. Newman S.P., Hirst P.H., Pitcairn G.R., Clark A.R. Understanding regional lung deposition in gamma scintigraphy. Dalby R.N., Byron P.R., Farr S.J., Respiratory Drug Delivery VI. 1998;9-15 Interpharm Press, Buffalo Grove.
18. Newman S.P. Scintigraphic assessment of pulmonary delivery systems. Pharm. Tech. 22:1998;78-94. June.
19. Newman S.P., Pitcairn G.R., Hirst P.H., Bacon R.E., O'Keefe E., Reiners M., Hermann R. Scintigraphic comparison of budsonide deposition from two dry powder inhalers. Eur. Respir. J. 16:2000a;178-183.
20. Newman S.P., Wilding I.R., Hirst P.H. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int. J. Pharm. 208:2000b;49-60.
21. Pauwels R.A., Hargreave F.E., Camus P., Bukoski M., Stahl E. A one-year comparison of Turbuhaler vs pressurised metered dose inhaler in asthmatic patients. Chest. 110:1996;53-57.
22. Pitcairn G.R., Newman S.P. Tissue attenuation corrections in gamma scintigraphy. J. Aerosol Med. 3:1997;187-198.
23. Pitcairn G.R., Lim J., Hollingworth A., Newman S.P. Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. J. Aerosol Med. 10:1997;295-306.
24. Pitcairn G.R., Lankinen T., Seppälä O.-P., Newman S.P. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J. Aerosol Med. 13:2000;97-104.
25. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.-C. Lung volumes and forced ventilatory flows. Eur. Respir. 6:(Suppl. 16):1993;5-40.
26. Snell N.J.C., Ganderton D. Assessing lung deposition of inhaled medications. Respir. Med. 93:1999;123-133.
27. Thorsson L., Newman S.P., Weisz A., Trofast E., Moren F. Nasal distribution of budesonide inhaled via a powder inhaler. Rhinology. 31:1993;7-10.
28. Thorsson L., Edsbäcker S., Conradson T.-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler p-MDI. Eur. Respir. J. 7:1994;1839-1844.
29. United States Pharmacopeia, 1996. General tests and assays Pharm. Forum. 22, 3048-3108.
30. Warren S.J., Taylor G. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (Clickhaler), a conventional metered dose inhaler and MDI plus spacer. Dalby R.N., Byron P.R., Farr S.J., Respiratory Drug Delivery VI. 1998;453-455 Interpharm Press, Buffalo Grove.
31. Warren, S., Taylor, G., Godfrey, C., Embleton, J.K., Buck, H., Birrell, C.E., Morton, D.A.V., Meakin, B.J., 1999. Budesonide Clickhaler formulation development: Does in vitro aerosol performance predict in vivo lung delivery? Proceedings of Drug Delivery to the Lungs X, The Aerosol Society, pp. 160-162.
32. Zanen P., Lammers J.W.J. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur. J. Clin. Pharmacol. 48:1995;179-184.